Vanguard Group Inc Relmada Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RLMD
# of Institutions
50Shares Held
5.82MCall Options Held
0Put Options Held
0-
Acadian Asset Management LLC Boston, MA619KShares$371,6870.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$343,9880.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$297,0870.03% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD397KShares$237,9080.04% of portfolio
-
Geode Capital Management, LLC Boston, MA302KShares$181,4120.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $17.2M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...